Treatment of sialorrhea by combined use of muscarinic M1 and M3 receptor selective antagonists

Treatment of sialorrhea by combined use of muscarinic M1 and M3 receptor selective antagonists - Treatment of sialorrhea by combined use of muscarinic M1 and M3 receptor selective antagonists

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031765

Enrollment

Registered

2018-04-01

Start date

2018-05-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sialorrhea

Interventions

Six weeks medication of sorifenacine 5 mg / day followed by conbined use of pirenzepin 75 mg/ day.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: true and/or psychogenic sialorrhea

Exclusion criteria

Exclusion criteria: retention sialorrhea

Design outcomes

Primary

Measure	Time frame
Sialorrhea Clinical Scale for PD during 12 weeks	—

Secondary

Measure	Time frame
salivary flow rate (rest and stimulated) during 12 weeks	—

Countries

Japan

Contacts

Public ContactYukie Yamamura

Tokyo Women's medical university Department of otolaryhgology

yamamura.yukie@twmu.ac.jp03-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026